GLP

GLP
Name	GLP
Formation	20th century
Purpose	Quality standards for non-clinical laboratory studies
Region	International

GLP

GLP is a set of quality principles for planning, performing, monitoring, recording, reporting, and archiving non-clinical safety studies. It was developed to ensure the reliability, reproducibility, and integrity of data submitted to regulatory authorities such as European Medicines Agency, United States Food and Drug Administration, Organisation for Economic Co-operation and Development, World Health Organization, and national agencies including Japan Ministry of Health, Labour and Welfare, Health Canada, and Australia Therapeutic Goods Administration.

Introduction

GLP defines organizational and procedural standards for laboratories and test facilities engaged in safety testing for products evaluated by European Commission, United States Congress, Food and Drug Administration Center for Drug Evaluation and Research, National Institutes of Health, Centers for Disease Control and Prevention, United States Environmental Protection Agency, and other regulators. It covers responsibilities of study directors, principal investigators, and quality assurance personnel associated with submissions to bodies such as the European Chemicals Agency, Chemical Weapons Convention Organization for the Prohibition of Chemical Weapons, and regional authorities like China National Medical Products Administration and Brazilian Health Regulatory Agency. International implementation draws on instruments and guidance from Organisation for Economic Co-operation and Development test guidelines, harmonization efforts by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and multinational accords such as the Helsinki Declaration in adjacent fields.

History and Development

The development of GLP traces to public scandals and regulatory responses in the mid-20th century, including incidents affecting Thalidomide, Agent Orange, and controversies involving laboratories tied to companies like Dow Chemical Company, Bayer, and Monsanto. Early catalysts included investigations by parliamentary committees in United Kingdom, congressional hearings in United States House Committee on Interstate and Foreign Commerce, and actions by agencies such as United States Food and Drug Administration and United States Environmental Protection Agency. The formalization of GLP arose from work by Organisation for Economic Co-operation and Development in the 1970s and 1980s and subsequent adoption by the European Commission via directives and by national legislatures including statutes in Japan, Canada, and Australia. Influential reports and guidelines from organizations like World Health Organization, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and standards bodies such as International Organization for Standardization shaped protocols, while litigation involving firms such as Pfizer, GlaxoSmithKline, and Johnson & Johnson reinforced enforcement priorities.

Principles and Requirements

Core GLP principles delineate roles for study directors, principal investigators, pathologists, and quality assurance units, and mandate written protocols, standard operating procedures, and defined data management systems acceptable to authorities including European Medicines Agency and United States Food and Drug Administration. Requirements cover facility design, equipment calibration traceable to agencies such as National Institute of Standards and Technology, test and control article characterization often referenced in dossiers submitted to European Chemical Agency or United Kingdom Medicines and Healthcare products Regulatory Agency, and archiving meeting expectations of courts in jurisdictions like United States District Court and administrative tribunals. Documentation standards align with practices advocated by International Organization for Standardization and audit trails recognized by agencies including United States Food and Drug Administration and Health Canada.

Applications and Scope

GLP applies to non-clinical safety tests for chemical substances, pharmaceuticals, agrochemicals, veterinary products, cosmetics, and industrial chemicals evaluated by European Chemicals Agency, United States Environmental Protection Agency, China National Center for Food Safety Risk Assessment, Brazilian Health Regulatory Agency, and regional regulatory authorities. Studies under GLP include toxicology, ecotoxicology, pharmacokinetics, and environmental fate investigations used in dossiers for approvals by European Commission, United States Food and Drug Administration Center for Drug Evaluation and Research, and authorization processes in markets such as Japan and India. Contract research organizations and academic laboratories that perform work for firms like Evotec, Charles River Laboratories International, Covance, and Eurofins Scientific often operate under GLP to support submissions to bodies including World Health Organization prequalification programs and procurement by United Nations agencies.

Regulatory Framework and Oversight

Regulatory frameworks integrate GLP into national law, guidance documents, and inspection programs administered by agencies such as United States Food and Drug Administration, European Medicines Agency, Japan Ministry of Health, Labour and Welfare, Health Canada, and Australian Therapeutic Goods Administration. International mutual acceptance arrangements, such as the Organisation for Economic Co-operation and Development Mutual Acceptance of Data, facilitate cross-border recognition of studies from GLP-compliant facilities in countries like Germany, France, Sweden, Italy, Spain, Netherlands, Denmark, Belgium, Ireland, Switzerland, Norway, Finland, Austria, Poland, Czech Republic, Hungary, Romania, Bulgaria, Greece, Portugal, Slovakia, Slovenia, Estonia, Latvia, Lithuania, Luxembourg, Croatia, Serbia, Turkey, South Korea, Singapore, New Zealand, South Africa, Mexico, Argentina, Chile, Colombia, Peru, and Ukraine.

Compliance, Inspections, and Enforcement

Compliance relies on routine and for-cause inspections by regulatory inspectors from agencies such as United States Food and Drug Administration and national competent authorities; enforcement can involve warning letters, data rejection by European Medicines Agency, revocation of marketing authorizations, and legal actions in courts including European Court of Justice and national judiciaries. Quality assurance units and external auditors from firms like KPMG, Deloitte, PricewaterhouseCoopers, and Ernst & Young may conduct internal audits, while accreditation bodies such as ISO affiliates provide certification frameworks referenced in procurement by organizations like World Bank and United Nations Development Programme.

Criticisms and Challenges

Critics including academics at University of Oxford, Harvard University, Stanford University, Massachusetts Institute of Technology, and policy analysts at Brookings Institution and Chatham House argue that GLP can be burdensome for small entities and may not fully address scientific validity issues raised in disputes involving firms like Monsanto and Bayer. Challenges include harmonizing interpretation across regulators such as European Medicines Agency and United States Food and Drug Administration, integrating new methodologies developed at institutions like ETH Zurich and Max Planck Society, and addressing reproducibility concerns highlighted by researchers at National Institutes of Health and editorial boards of journals like Nature and Science.

Category:Laboratory standards